Ejection fraction improvement by β-blocker treatment in patients with heart failure: An analysis of studies published in the literature

Journal of Cardiovascular Pharmacology

Volumn 32, Issue SUPPL. 1, 1998, Pages

  Van Campen, Linda C M C ^a   Visser, Frans C ^a   Visser, Cees A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blockade; Carvedilol; Ejection fraction; Left ventricular dysfunction

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL; NEBIVOLOL; PROPRANOLOL;

ANALYTIC METHOD; BETA ADRENERGIC RECEPTOR BLOCKING; CATECHOLAMINE RELEASE; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; HEART EJECTION FRACTION; HEART FAILURE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE;

ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL ISCHEMIA; OUTCOME ASSESSMENT (HEALTH CARE); STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031715940     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800003-00006     Document Type: Conference Paper

References (50)

1. Unverferth DV, Magorien R, Moeshberger M, Baker P, Fetters J, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-52.
2. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987;59:634-8.
3. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988;62-25A-30A.
4. Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989;14:564-70.
5. Waagstein F, Hjalmarson A, Vamauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
6. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334: 1349-55.
7. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
8. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342:1441-6.
9. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol 1994;23:814-21.
10. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41.
11. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C.
12. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-16.
13. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985; 17:291-306.
14. Opie L. Effects of catecholamines on normal myocardium: implications for the failing heart. Heart Fail 1986;3:104-9.
15. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85:790-804.
16. Michelakis AM, McAllister RG. The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab 1972;34:386-94.
17. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
18. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-9.
19. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
20. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
21. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-6.
22. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-33.
23. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-63.
24. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72: 536-46.
25. Waagstein F, Hjalmarson A, Swedberg K, Wallentin I. Beta-blockers in dilated cardiomyopathies: they work. Eur Heart J 1983;4(suppl A):173-8.
26. Sano H, Kawabata N, Yonezawa K, Hirayama H, Sakuma I, Yasuda H. Metoprolol was more effective than captopril for dilated cardiomyopathy in Japanese patients. Circulation 1989;89(suppl II):II-118.
27. Waagstein F, Blomstrom-Lundquist C, Andersson B, Hjalmarson A, Wallentin I. Long-term effects of metoprolol in severe heart failure due to ischemic cardiomyopathy, primary valve disease and diabetes. Circulation 1987;76(suppl IV):IV-358.
28. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemo-dynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-90.
29. Bennett SK, Fisher ML, Krichten C, Patten RD, Greenberg NL, Gottlieb SS. Heart failure with known coronary artery disease: comparison of changes in ejection fraction with beta-blocker and placebo [Abstract]. J Am Coll Cardiol 1993;21:114A.
30. Currie PJ, Kelly MJ, McKenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984;3:203-9.
31. Nemanich JW, Veith RC, Abrass IB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 1990;66: 843-8.
32. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-50.
33. Heesch CM, Marcoux L, Hatfield B, Eichhorn EJ. Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Am J Cardiol 1995;75: 360-4.
34. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
35. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of synpathetic-induced alterations of immunologic function. Circulation 1994;90:1774-80.
36. Andersson B, Caidahl K, Waagstein F. Recovery from left ventricular asynergy in ischemic cardiomyopathy following long-term beta blockade treatment. Cardiology 1994;85:14-22.
37. Das Gupta P, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118-23.
38. Metra M, Nardi M, Giubbini R, Dei CL. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
39. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8.
40. Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 1996;131:337-41.
41. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-6.
42. Quaife RA, Gilbert EM, Christian PE, et al. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol 1996;78:779-84.
43. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
44. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation 1994;89:1632-42.
45. Eichhorn EJ, Heesch CM, Risser RC, Marcoux L, Hatfield B. Predictors of systolic and diastolic improvements in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol 1995;25:154-62.
46. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66:603-7.
47. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990; 82:473-83.
48. Rousseau MF, Chapelle F, Van EC, et al. Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Cardiac Fail 1996;2: 15-23.
49. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-100.
50. Erlebacher JA, Bhardwaj M, Suresh A, Leber GB, Goldweit RS. Beta-blocker treatment of idiopathic and ischemic dilated cardiomyopathy in patients with ejection fractions < or =20%. Am J Cardiol 1993;71:1467-9.